Companies:
50,705
Total Market Cap:
148169918078737.70
Global Rank
#28434
Country Rank
#379
Market Cap
66.24 M
Price
0.026
Change (%)
6.19%
Volume
27.91 M
Xbrane Biopharma AB (publ)'s latest marketcap:
66.24 M
As of 09/26/2025, Xbrane Biopharma AB (publ)'s market capitalization has reached $66.24 M. According to our data, Xbrane Biopharma AB (publ) is the 28434th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 66.24 M |
| Revenue (ttm) | 28.12 M |
| Net Income (ttm) | 8.4 M |
| Shares Out | 2.55 B |
| EPS (ttm) | 0.01 |
| Forward PE | 4.92 |
| Ex-Dividend Date | n/a |
| Earnings Date | 10/24/2025 |
Market Cap Chart
Data Updated: 09/26/2025
Xbrane Biopharma AB (publ)'s yearly market capitalization.
Xbrane Biopharma AB (publ) has seen its market value grow from kr192.6 M to kr626.2 M since 2016, representing a total increase of 225.13% and an annual compound growth rate (CAGR) of 14.44%.
| Date | Market Cap(kr) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 09/26/2025 | kr626.2 M | $66.24 M | 172.03% | 28434 |
| 12/30/2024 | kr245.94 M | $22.11 M | -17.28% | 33542 |
| 12/29/2023 | kr297.31 M | $29.31 M | -86.83% | 31316 |
| 12/30/2022 | kr2.26 B | $215.44 M | -13.94% | 17594 |
| 12/30/2021 | kr2.62 B | $288.66 M | 58.03% | 16692 |
| 12/30/2020 | kr1.66 B | $200.93 M | 211.34% | 16749 |
| 12/30/2019 | kr533.37 M | $56.7 M | 83.6% | 21216 |
| 12/28/2018 | kr290.51 M | $32.65 M | -25.82% | 23183 |
| 12/29/2017 | kr391.66 M | $47.63 M | 103.35% | 21831 |
| 12/30/2016 | kr192.6 M | $21.07 M | 23056 |
Company Profile
About Xbrane Biopharma AB (publ)
Xbrane Biopharma AB (publ) is a biotechnology company specializing in the development, manufacturing, and commercialization of biosimilars. Founded in 2008, the company is headquartered in Solna, Sweden.
Key Products
- Ximluci: A ranibizumab biosimilar used to treat wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults.
Pre-Clinical Pipeline
- BIIB801: A certolizumab pegol biosimilar candidate targeting rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, psoriasis, Crohn’s disease, and axial spondylitis.
- Xdivane: A nivolumab biosimilar candidate for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder/urinary tract cancer.
- Xdarzane: A daratumumab biosimilar candidate indicated for multiple myeloma.
Frequently Asked Questions
-
What is Xbrane Biopharma AB (publ)'s (STO-XBRANE) current market cap?As of 09/26/2025, Xbrane Biopharma AB (publ) (including the parent company, if applicable) has an estimated market capitalization of $66.24 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Xbrane Biopharma AB (publ) (STO-XBRANE) rank globally by market cap?Xbrane Biopharma AB (publ) global market capitalization ranking is approximately 28434 as of 09/26/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.